ICICI Prudential Nifty Pharma Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹81 Cr
Expense Ratio
0.97%
ISIN
INF109KC18L6
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
15 Dec 2022
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹16.06, Assets Under Management (AUM) of 80.60 Crores, and an expense ratio of 0.97%.
- ICICI Prudential Nifty Pharma Index Fund Regular Growth has given a CAGR return of 22.76% since inception.
- The fund's asset allocation comprises around 99.32% in equities, 0.00% in debts, and 0.68% in cash & cash equivalents.
- You can start investing in ICICI Prudential Nifty Pharma Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.37%
— (Cat Avg.)
Since Inception
+22.76%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹80.05 Cr | 99.32% |
| Others | ₹0.55 Cr | 0.68% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹19.94 Cr | 24.74% |
| Cipla Ltd | Equity | ₹8.65 Cr | 10.73% |
| Divi's Laboratories Ltd | Equity | ₹7.82 Cr | 9.70% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.44 Cr | 9.23% |
| Lupin Ltd | Equity | ₹5.22 Cr | 6.48% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.6 Cr | 4.46% |
| Aurobindo Pharma Ltd | Equity | ₹3.46 Cr | 4.29% |
| Mankind Pharma Ltd | Equity | ₹2.92 Cr | 3.62% |
| Alkem Laboratories Ltd | Equity | ₹2.77 Cr | 3.43% |
| Laurus Labs Ltd | Equity | ₹2.56 Cr | 3.18% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.47 Cr | 3.07% |
| Zydus Lifesciences Ltd | Equity | ₹2.36 Cr | 2.93% |
| Ipca Laboratories Ltd | Equity | ₹2.22 Cr | 2.76% |
| Abbott India Ltd | Equity | ₹1.71 Cr | 2.12% |
| Biocon Ltd | Equity | ₹1.64 Cr | 2.04% |
| Gland Pharma Ltd | Equity | ₹1.35 Cr | 1.68% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.24 Cr | 1.54% |
| Ajanta Pharma Ltd | Equity | ₹1.18 Cr | 1.46% |
| Treps | Cash - Repurchase Agreement | ₹0.98 Cr | 1.22% |
| Natco Pharma Ltd | Equity | ₹0.76 Cr | 0.95% |
| Granules India Ltd | Equity | ₹0.75 Cr | 0.93% |
| Net Current Assets | Cash | ₹-0.44 Cr | 0.54% |
Allocation By Market Cap (Equity)
Large Cap Stocks
61.79%
Mid Cap Stocks
29.26%
Small Cap Stocks
8.27%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹80.05 Cr | 99.32% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nishit Patel
Since December 2022
Ashwini Shinde
Since December 2024
Additional Scheme Detailsas of 31st March 2025
ISIN INF109KC18L6 | Expense Ratio 0.97% | Exit Load No Charges | Fund Size ₹81 Cr | Age 2 years 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
| Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
| Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
About the AMC
ICICI Prudential Mutual Fund
Total AUM
₹8,67,406 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Other Funds by ICICI Prudential Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
What is the portfolio composition of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
Who manages the ICICI Prudential Nifty Pharma Index Fund Regular Growth?
- Nishit Patel
- Ashwini Shinde
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
ICICI Prudential Nifty Pharma Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹81 Cr
Expense Ratio
0.97%
ISIN
INF109KC18L6
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
15 Dec 2022
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹16.06, Assets Under Management (AUM) of 80.60 Crores, and an expense ratio of 0.97%.
- ICICI Prudential Nifty Pharma Index Fund Regular Growth has given a CAGR return of 22.76% since inception.
- The fund's asset allocation comprises around 99.32% in equities, 0.00% in debts, and 0.68% in cash & cash equivalents.
- You can start investing in ICICI Prudential Nifty Pharma Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.37%
— (Cat Avg.)
Since Inception
+22.76%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹80.05 Cr | 99.32% |
| Others | ₹0.55 Cr | 0.68% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹19.94 Cr | 24.74% |
| Cipla Ltd | Equity | ₹8.65 Cr | 10.73% |
| Divi's Laboratories Ltd | Equity | ₹7.82 Cr | 9.70% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.44 Cr | 9.23% |
| Lupin Ltd | Equity | ₹5.22 Cr | 6.48% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.6 Cr | 4.46% |
| Aurobindo Pharma Ltd | Equity | ₹3.46 Cr | 4.29% |
| Mankind Pharma Ltd | Equity | ₹2.92 Cr | 3.62% |
| Alkem Laboratories Ltd | Equity | ₹2.77 Cr | 3.43% |
| Laurus Labs Ltd | Equity | ₹2.56 Cr | 3.18% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.47 Cr | 3.07% |
| Zydus Lifesciences Ltd | Equity | ₹2.36 Cr | 2.93% |
| Ipca Laboratories Ltd | Equity | ₹2.22 Cr | 2.76% |
| Abbott India Ltd | Equity | ₹1.71 Cr | 2.12% |
| Biocon Ltd | Equity | ₹1.64 Cr | 2.04% |
| Gland Pharma Ltd | Equity | ₹1.35 Cr | 1.68% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.24 Cr | 1.54% |
| Ajanta Pharma Ltd | Equity | ₹1.18 Cr | 1.46% |
| Treps | Cash - Repurchase Agreement | ₹0.98 Cr | 1.22% |
| Natco Pharma Ltd | Equity | ₹0.76 Cr | 0.95% |
| Granules India Ltd | Equity | ₹0.75 Cr | 0.93% |
| Net Current Assets | Cash | ₹-0.44 Cr | 0.54% |
Allocation By Market Cap (Equity)
Large Cap Stocks
61.79%
Mid Cap Stocks
29.26%
Small Cap Stocks
8.27%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹80.05 Cr | 99.32% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nishit Patel
Since December 2022
Ashwini Shinde
Since December 2024
Additional Scheme Detailsas of 31st March 2025
ISIN INF109KC18L6 | Expense Ratio 0.97% | Exit Load No Charges | Fund Size ₹81 Cr | Age 2 years 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
| Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
| Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
About the AMC
ICICI Prudential Mutual Fund
Total AUM
₹8,67,406 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Other Funds by ICICI Prudential Mutual Fund
Related Articles
Still got questions?
We're here to help.
What is the current NAV of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
What is the portfolio composition of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
Who manages the ICICI Prudential Nifty Pharma Index Fund Regular Growth?
- Nishit Patel
- Ashwini Shinde
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
